Cardiac effects in perinatally HIV-infected and HIV-exposed but uninfected children and adolescents: A view from the United States of America

Journal of the International AIDS Society

Volumn 16, Issue , 2013, Pages

  Lipshultz, Steven E ^a   Miller, Tracie L ^a   Wilkinson, James D ^a   Scott, Gwendolyn B ^a   Somarriba, Gabriel ^a   Cochran, Thomas R ^a   Fisher, Stacy D ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Antiretroviral therapies; Cardiac outcomes; Cardiovascular risk; Child; HIV; Therapeutic complications

Indexed keywords

ALDOSTERONE ANTAGONIST; ANTIRETROVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADOLESCENT DISEASE; AIDS PATIENT; ATHEROSCLEROSIS; AUTONOMIC DYSFUNCTION; BACTERIAL ENDOCARDITIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MALFORMATION; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CHILDHOOD DISEASE; CORONARY RISK; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE TRANSMISSION; ENDOCARDITIS; HEART CANCER; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE SIZE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LYMPHOMA; MORTALITY; MOTHER; MYOCARDITIS; NONHUMAN; NUTRITIONAL DEFICIENCY; NUTRITIONAL STATUS; PATHOGENESIS; PERICARDIAL EFFUSION; PERINATAL PERIOD; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; QT PROLONGATION; REVIEW; SUDDEN CARDIAC DEATH; UNITED STATES; VASCULITIS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ANTIRETROVIRAL THERAPIES; CARDIAC OUTCOMES; CHILD; HUMAN IMMUNODEFICIENCY VIRUS; PREVALENCE; THERAPEUTIC COMPLICATIONS;

AIDS; ANTIRETROVIRAL THERAPIES; CARDIAC OUTCOMES; CARDIOVASCULAR RISK; CHILD; HIV; THERAPEUTIC COMPLICATIONS;

ADOLESCENT; CARDIOVASCULAR DISEASES; CHILD; HIV INFECTIONS; HUMANS; PREVALENCE; UNITED STATES;

EID: 84887299913     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.16.1.18597     Document Type: Review

References (126)

1. Currie PF, Jacob AJ, Foreman AR, Elton RA, Brettle RP, Boon NA. Heart muscle disease related to HIV infection: prognostic implications. BMJ. 1994;309:1605.
2. Lipshultz SE, Orav EJ, Sanders SP, Colan SD. Immunoglobulins and left ventricular structure and function in pediatric HIV infection. Circulation. 1995;92:2220-5.
3. Saidi A, Bricker JT. Pulmonary hypertension in patients infected with HIV. In: Lipshultz SE, editor. Cardiology in AIDS. New York: Chapman & Hall; 1998. p. 187-94.
4. Jenson HB, Pollock BH. Cardiac cancers in HIV-infected patients. In: Lipshultz SE, editor. Cardiology in AIDS. New York: Chapman & Hall; 1998. p. 255-63.
5. 2 HIV) study group. Circulation. 2000;102:1542-8.
6. Morse CG, Kovacs JA. Metabolic and skeletal complications of HIV infection: the price of success. JAMA. 2006;296:844-54.
7. Lipshultz SE, Fisher SD, Miller TL, Sharma TS, Milton AN. The cardiovascular manifestations of HIV infection. Dialog Cardiovasc Med. 2007;12(1):5-23.
8. Zareba KM, Miller TL, Lipshultz SE. Cardiovascular disease and toxicities related to HIV infection and its therapies. Expert Opin Drug Saf. 2005;4(6):1017-25.
9. Zareba KM, Lipshultz SE. Cardiovascular complications in patients with HIV infection. Curr Infect Dis Rep. 2003;5(6):513-20.
10. Barbaro G, Fisher SD, Lipshultz SE. Pathogenesis of HIV-associated cardiovascular complications. Lancet Infect Dis. 2001;1(2):115-24.
11. Keesler MJ, Fisher SD, Lipshultz SE. Cardiac manifestations of HIV infection in infants and children. Ann N Y Acad Sci. 2001;946:169-78.
12. 2 study. Pediatrics. 2001;107(2):328-38.
13. 2 HIV) study group, national heart, lung, and blood institute. Pediatrics. 1999;104(2):14.
14. 2 HIV) study group. Circulation. 1998;97(13):1246-56.
15. Epstein JE, Eichbaum QG, Lipshultz SE. Cardiovascular manifestations of HIV infection. Compr Ther. 1996;22(8):485-91.
16. Lane-McAuliffe EM, Lipshultz SE. Cardiovascular manifestations of pediatric HIV infection. Nurs Clin North Am. 1995;30(2):291-316.
17. Luginbuhl LM, Orav EJ, McIntosh K, Lipshultz SE. Cardiac morbidity and related mortality in children with HIV infection. JAMA. 1993;269(22):2869-75.
18. Patel N, Abdelsayed S, Veve M, Miller CD. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens. Ann Pharmacother. 2011;45(3):317-24.
19. Mas CM, Miller TL, Cordero C, Dauphin D, White MD, Vila CK, et al. The effects of fetal and childhood exposure to antiretroviral agents, J AIDS Clin Res. 2011;S2:001.
20. Fisher SD, Kanda BS, Miller TL, Lipshultz SE. Cardiovascular disease and therapeutic drug-related cardiovascular consequences in HIV-infected patients. Am J Cardiovasc Drugs. 2011;11(6):383-94.
21. Dubé MP, Lipshultz SE, Fichtenbaum CJ, Greenberg R, Schecter AD, Fisher SD. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation. 2008;118(2):e36-40.
22. Fisher SD, Miller TL, Lipshultz SE. Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. Atherosclerosis. 2006;185(1):1-11.
23. UNAIDS. 2012 Report on the Global AIDS epidemic. http://www.unaids.org.
24. 2 HIV multicenter study. Am Heart J. 2005;150(3):439-47.
25. Lipshultz SE. Dilated cardiomyopathy in HIV-infected patients. N Engl J Med. 1998;339(16):1153-5.
26. Harmon WG, Dadlani GH, Fisher SD, Lipshultz SE. Myocardial and pericardial disease in HIV. Curr Treat Options Cardiovasc Med. 2002;4(6):497-509.
27. Fitch K, Grinspoon S. Nutritional and metabolic correlates of cardiovascular and bone disease in HIV-infected patients. Am J Clin Nutr. 2011;94(6):1721S-8S.
28. Carr A, Samaras K, Chisholm DJ, Cooper DA. Abnormal fat distribution and use of protease inhibitors. Lancet. 1998;351(9117):1736.
29. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352(1):48-62.
30. Palella FJ, Jr., Phair JP. Cardiovascular disease in HIV infection. Curr Opin HIV AIDS. 2011;6(4):266-71.
31. Friis-Moller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients-ssociation with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17(8):1179-93.
32. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17(17):2479-86.
33. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. Practice guideline: 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60:e44-e164.
34. Arpadi SM, Bethel J, Horlick M, Sarr M, Bamji M, Abrams EJ, et al. Longitudinal changes in regional fat content in HIV-infected children and adolescents. AIDS. 2009;23(12):1501-9.
35. Jacobson DL, Patel K, Siberry GK, Van Dyke RB, DiMeglio LA, Geffner ME, et al. Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study. Am J Clin Nutr. 2011;94(6):1485-95.
36. Geffner ME, Patel K, Miller TL, Hazra R, Silio M, Van Dyke RB, et al. Factors associated with insulin resistance among children and adolescents perinatally infected with HIV-1 in the pediatric HIV/AIDS cohort study. Horm Res Paediatr. 2011;76(6):386-91.
37. Miller TL, Borkowsky W, DiMeglio LA, Dooley L, Geffner ME, Hazra R, et al. Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children. HIV Med. 2012;13(5):264-75.
38. Miller TL, Orav EJ, Lipshultz SE, Arheart KL, Duggan C, Weinberg GA, et al. Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1. J Pediatr. 2008;153(4):491-7.
39. Sanchez Torres AM, Munoz Muniz R, Madero R, Borque C, Garcia-Miguel MJ, De Jose Gomez MI. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr. 2005;164(5):271-6.
40. Brambilla P, Bricalli D, Sala N, Renzetti F, Manzoni P, Vanzulli A, et al. Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy. AIDS. 2001;15(18):2415-22.
41. Moscicki AB, Ellenberg JH, Murphy DA, Jiahong X. Associations among body composition, androgen levels, and human immunodeficiency virus status in adolescents. J Adolesc Health. 2006;39(2):164-73.
42. Miller TL, Mawn BE, Orav EJ, Wilk D, Weinberg GA, Nicchitta J, et al. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. Pediatrics. 2001;107(5):E77.
43. Aldrovandi GM, Lindsey JC, Jacobson DL, Zadzilka A, Sheeran E, Moye J, et al. Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS. 2009;23(6):661-72.
44. Boccara F, Teiger E, Cohen A, Ederhy S, Janower S, Odi G, et al. Percutaneous coronary intervention in HIV infected patients: immediate results and long term prognosis. Heart. 2006;92:543-4.
45. Vigano A, Mora S, Testolin C, Beccio S, Schneider L, Bricalli D, et al. Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J Acquir Immune Defic Syndr. 2003;32(5):482-9.
46. Arpadi SM, Cuff PA, Horlick M, Wang J, Kotler DP. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ -lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr. 2001;27(1):30-4.
47. Gerschenson M, Shiramizu B, LiButti DE, Shikuma CM. Mitochondrial DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals. Antivir Ther. 2005;10(Suppl 2):M83-9.
48. Sztam KA, Jiang H, Jurgrau A, Deckelbaum RJ, Foca MD. Early increases in concentrations of total, LDL, and HDL cholesterol in HIV-infected children following new exposure to antiretroviral therapy. J Pediatr Gastroenterol Nutr. 2011;52(4):495-8.
49. Rhoads MP, Lanigan J, Smith CJ, Lyall EG. Effect of specific ART drugs on lipid changes and the need for lipid management in children with HIV. J Acquir Immune Defic Syndr. 2011;57(5):404-12.
50. Jacobson DL, Williams P, Tassiopoulos K, Melvin A, Hazra R, Farley J. Clinical management and follow-up of hypercholesterolemia among perinatally HIV-infected children enrolled in the PACTG 219C study. J Acquir Immune Defic Syndr. 2011;57(5):413-20.
51. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl, 2012.
52. NHLBI AIDS working group. http://www.nhlbi.nih.gov/meetings/workshops/ AIDSworking.htm, September 6-7, 2012, Bethesda, MD.
53. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129-38.
54. Longenecker C, Hoit B. Imaging atherosclerosis in HIV: carotid intimamedia thickness and beyond. Translational research: J Lab Clin Med. 2012;159(3):127-39.
55. Miller TL, Somarriba G, Orav EJ, Mendez AJ, Neri D, Schaefer N, et al. Biomarkers of vascular dysfunction in children infected with human immunodeficiency virus-1. J Acquir Immune Defic Syndr. 2010;55(2):182-8.
56. Foster SB, Lu M, Glaze DG, Reuben JM, Harris LL, Cohen EN, et al. Associations of cytokines, sleep patterns, and neurocognitive function in youth with HIV infection. Clin Immunol. 2012;144(1):13-23.
57. DAD Study Group, Friis-Moller N, Reiss P, Sabin CA,Weber R, Monforte AD, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-35.
58. Cruse B, Cysique LA, Markus R, Brew BJ. Cerebrovascular disease in HIV-infected individuals in the era of highly active antiretroviral therapy. J Neurovirol. 2012;18(4):264-76.
59. Lazzaretti RK, Kuhmmer R, Sprinz E, Polanczyk CA, Ribeiro JP. Clinical research: dietary intervention prevents dyslipidemia associated with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected individuals. A randomized trial. J Am Coll Cardiol. 2012;59:979-88.
60. Somarriba G, Lopez-Mitnik G, Ludwig DA, Neri D, Schaefer N, Lipshultz SE, et al. Physical fitness in children infected with the human immunodeficiency virus: associations with highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 2013;29(1):112-20.
61. Dubé MP, Cadden JJ. Lipid metabolism in treated HIV Infection. Best Practice Res Clin Endocrinol Metab. 2011;25(3):429-42.
62. Lipshultz SE, Mas CM, Henkel JM, Franco VI, Fisher SD, Miller TL. HAART to heart: highly active antiretroviral therapy and the risk of cardiovascular disease in HIV-infected or exposed children and adults. Exp Rev Anti Infect Ther. 2012;10(6):661-74.
63. Butt AA, Chang CC, Kuller L, Goetz MB, Leaf D, Rimland D, et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med. 2011;171(8):737-43.
64. Mondy KE, Gottdiener J, Overton ET, Henry K, Bush TC, et al. High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy. Clin Infect Dis. 2011;52(3):378-86.
65. Lipshultz SE, Williams PL, Wilkinson JD, Leister EC, Van Dyke RB, Shearer WT, et al. Cardiac status of HIV-infected children treated with long-term combination antiretroviral therapy: results from the Adolescent Master Protocol of the NIH multicenter pediatric HIV/AIDS cohort study. JAMA Pediatr. 2013; Apr 22:1-8 [Epub ahead of print].
66. Zareba KM, Lavigne JE, Lipshultz SE. Cardiovascular effects of HAART in infants and children of HIV-infected mothers. Cardiovasc Toxicol. 2004;4(3):271-9.
67. 2 HIV): a cohort study. Lancet. 2002;360(9330):368-73.
68. Lipshultz SE, Shearer WT, Thompson B, Rich KC, Cheng I, Orav EJ, et al. Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIV-Exposed Infants and Children cohort study). J Am Coll Cardiol. 2011;57(1):76-85.
69. Wilkinson JD, Williams PL, Leister E, Zeldow B, Shearer WT, Colan SD, et al. Cardiac biomarkers in HIV-exposed uninfected children: the pediatric HIV/AIDS cohort study (PHACS). AIDS. 2013; 27(7):1099-108.
70. Grossi PA. Update in HIV infection in organ transplantation. Curr Opin Organ Transplant. 2012;17(6):586-93.
71. Pozzan G, Pagliari C, Tuon FF, Takakura CF, Kauffman MR, Duarte MI. Diffuse-regressive alterations and apoptosis of myocytes: possible causes of myocardial dysfunction in HIV-related cardiomyopathy. Int J Cardiol. 2009;132(1):90-5.
72. Bowles NE, Kearney DL, Ni J, Perez-Atayde AR, Kline MW, Bricker JT, et al. The detection of viral genomes by polymerase chain reaction in the myocardium of pediatric patients with advanced HIV disease. J Am Coll Cardiol. 1999;34(3):857-65.
73. Rogers JS, Zakaria S, Thom KA, Flammer KM, Kanno M, Mehra MR. Immune reconstitution inflammatory syndrome and human immunodeficiency virus-associated myocarditis. Mayo Clin Proc. 2008;83(11):1275-9.
74. Yearley JH, Mansfield KG, Carville AAL, Sokos GG, Xia D, Pearson CB, et al. Antigenic stimulation in the simian model of HIV infection yields dilated cardiomyopathy through effects of TNF α. AIDS. 2008;22(5):585-94.
75. Reinsch N, Neuhaus K, Esser S, Potthoff A, Hower M, Brockmeyer NH, et al. Prevalence of cardiac diastolic dysfunction in HIV-infected patients: results of the HIV-HEART study. HIV Clin Trials. 2010;11(3):156-62.
76. Lipshultz SE, Orav EJ, Sanders SP, Hale AR, McIntosh K, Colan SD. Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. N Engl J Med. 1992;327(18):1260-5.
77. Lipshultz SE, Orav EJ, Sanders SP, McIntosh K, Colan SD. Limitations of fractional shortening as an index of contractility in pediatric patients infected with human immunodeficiency virus. J Pediatr. 1994;125(4):563-70.
78. Lipshultz SE, Shearer WT, Thompson B, Rich K, Cheng I, Orav EJ, et al. Antiretroviral therapy (ART) cardiac effects in HIV-infected children: the multicenter NHLBI Cardiac Highly Active Antiretroviral Therapy (CHAART-II) study. Circulation. 2009;120:S909-10.
79. Hulten E, Mitchell J, Scally J, Gibbs B, Villines TC. HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies. Heart. 2009;95:1826-35.
80. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201:318-30.
81. Nayak G, Ferguson M, Tribble DR, Porter CK, Rapena R, Marchicelli M, et al. Cardiac diastolic dysfunction is prevalent in HIV-infected patients. AIDS Patient Care STDs. 2009;23(4):231-8.
82. O'Brien S, Sasaki N, Eidem BW, Colan SD, Cheng I, Wilkinson JD, et al. Left ventricular diastolic dysfunction in HIV-negative infants exposed in utero to antiretroviral therapy from HIV-positive mothers: the prospective NHLBI CHAART-I study. Circulation. 2011;124:A10808.
83. Halley CM, Houghtaling PL, Khalil MK, Thomas JD, Jaber WA. Mortality rate in patients with diastolic dysfunction and normal systolic function. Arch Intern Med. 2011;171(12):1082-7.
84. McMahon CJ, Nagueh SF, Pignatelli RH, Denfield SW, Dreyer WJ, Price JF, et al. Characterization of left ventricular diastolic function by tissue Doppler imaging and clinical status in children with hypertrophic cardiomyopathy. Circulation. 2004;109(14):1756-62.
85. McMahon CJ, Nagueh SF, Eapen RS, Dreyer WJ, Finkelshtyn I, Cao X, et al. Echocardiographic predictors of adverse clinical events in children with dilated cardiomyopathy: a prospective clinical study. Heart. 2004;90(8):908-15.
86. Ingul CB, Tjonna AE, Stolen TO, Stoylen A, Wisloff U. Impaired cardiac function among obese adolescents: effect of aerobic interval training. Arch Pediatr Adolesc Med. 2010;164(9):852-9.
87. Wojcik M, Rudzinski A, Starzyk J. Left ventricular diastolic dysfunction in adolescents with type 1 diabetes reflects the long- but not short-term metabolic control. J Pediatr Endocrinol Metab. 2010;23(10):1055-64.
88. Plazak W, Kopec G, Tomkiewicz-Pajak L, Rubis P, Dziedzic H, Suchon E, et al. Heart structure and function in patients with generalized autoimmune diseases: echocardiography with tissue Doppler study. Acta Cardiol. 2011;66(2):159-65.
89. Cade WT, Waggoner AD, Hubert S, Krauss MJ, Singh GK, Overton ET. Reduced diastolic function and left ventricular mass in HIV-negative preadolescent children exposed to antiretroviral therapy in utero. AIDS. 2012;26(16):2053-8.
90. Kelly KM, Tarwater PM, Karper JM, Bedia D, Queen SE, Tunin RS. Diastolic dysfunction is associated with myocardial viral load in simian immunodeficiency virus-infected macaques. AIDS. 2012;26(7):815-23.
91. Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS. 2008;22(Suppl 3):S35.
92. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119(16):2250-94.
93. Cicalini S, Almodovar S, Grilli E, Flores S. Pulmonary hypertension and human immunodeficiency virus infection: epidemiology, pathogenesis, and clinical approach. Clin Microbiol Infect. 2011;17(1):25-33.
94. Janda S, Quon B, Swiston J. HIV and pulmonary arterial hypertension: a systematic review. HIV and pulmonary arterial hypertension. HIV Med. 2011;11(10):620-34.
95. Lindl A, Reinschl N, Nehausl K, Esser S, Brockmeyer NH, Potthoff A, et al. Pericardial effusion of HIV-infected patients - results of a prospective multicenter cohort study in the era of antiretroviral therapy. Eur J Med Res. 2011;16:480-3.
96. Bolt RJ, Rammeloo LA, van Furth AM, van Well GT. A 15-year-old girl with a large pericardial effusion. Eur J Pediatr. 2008;167(7):811-2.
97. Yoon SA, Hahn YS, Hong JM, Lee OJ, Han HS. Tuberculous pericarditis presenting as multiple free floating masses in pericardial effusion. J Korean Med Sci. 2012;27(3):325-8.
98. Rapose A, Sarvat B, Sarria JC. Immune reconstitution inflammatory syndrome presenting as pericarditis and pericardial effusion. Cardiology. 2008;110(2):142-4.
99. Reuter H, Burgess LJ, Louw VJ, Doubell AF. The management of tuberculous pericardial effusion: experience in 233 consecutive patients. Cardiovasc J S Afr. 2007;18(1):20-5.
100. Van Doorn CA, Yates R, Tsang VT. Endocarditis as the first presentation of AIDS in infancy. Arch Dis Child. 1998;79(2):179-80.
101. Steinherz LJ, Brochstein JA, Robins J. Cardiac involvement in congenital acquired immunodeficiency syndrome. Am J Dis Child. 1986;140(12):1241-4.
102. Granovsky MO, Mueller BU, Nicholson HS, Rosenberg PS, Rabkin CS. Cancer in human immunodeficiency virus-infected children: a case series from the Children's Cancer Group and the National Cancer Institute. J Clin Oncol. 1998;16(5):1729-35.
103. Buck BE, Scott GB, Valdes-Dapena M, Parks WP. Kaposi sarcoma in two infants with acquired immune deficiency syndrome. J Pediatr. 1983;103(6):911-3.
104. Zoufaly A, Stellbrink HJ, Heiden MA, Kollan C, Hoffmann C, van Lunzen J, et al. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis. 2009;200(1):79-87.
105. Karavidas A, Tsiachris D, Lazaros G, Xylomenos G, Arapi S, Potamitis N, et al. Doppler tissue imaging unmasks right ventricular function abnormalities in HIV-infected patients. Cardiol J. 2010;17(6):587-93.
106. Guillevin L. Vasculitides in the context of HIV infection. AIDS. 2008;22(3):S27-33.
107. Tseng ZH, Secemsky EA, Dowdy D, Vittinghoff E, Moyers B, Wong JK, et al. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol. 2012;59:1891-6.
108. Sani MU, Okeahialam BN. QTc interval prolongation in patients with HIV and AIDS. J Natl Med Assoc. 2005;97:1657-61.
109. Nordin C, Kohli A, Beca S, Zaharia V, Grant T, Leider J, et al. Importance of hepatitis C coinfection in the development of QT prolongation in HIV-infected patients. J Electrocardiol. 2006;39:199-205.
110. Soliman EZ, Lundgren JD, Roediger MP, Duprez DA, Temesgen Z, Bickel M, et al. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS. 2011;25(3):367-77.
111. Correia D, Rodrigues De Resende LA, Molina RJ, Ferreira BD, Colombari F, Barbosa CJ, et al. Power spectral analysis of heart rate variability in HIV-infected and AIDS patients. Pacing Clin Electrophysiol. 2006;29:53-8.
112. Dapena M, Jiménez B, Noguera-Julian A, Soler-Palacín P, Fortuny C, Lahoz R, et al. Metabolic disorders in vertically HIV-infected children: future adults at risk for cardiovascular disease. J Pediatr Endocrinol Metab. 2012;25(5-6):529-35.
113. Piloya T, Bakeera-Kitaka S, Kekitiinwa A, Kamya MR. Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study. J Int AIDS Soc. 2012;15(2):17427.
114. Lang S, Mary-Krause M, Cotte L, Gilguin J, Partisani M, Simon A, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med. 2010;170:1228-38.
115. Lipshultz SE, Orav EJ, Sanders SP, Hale AR, McIntosh K, Colan SD. Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. N Engl J Med. 1992;327(18):1260-5.
116. Crain MJ, Chernoff MC, Oleske JM, Brogly SB, Malee KM, Borum PR, et al. Possible mitochondrial dysfunction and its association with antiretroviral therapy use in children perinatally infected with HIV. J Infect Dis. 2010;202(2):291-301.
117. Chanock SJ, Luginbuhl LM, McIntosh K, Lipshultz SE. Life-threatening reaction to trimethoprim/sulfamethoxazole in pediatric human immunodeficiency virus infection. Pediatrics. 1994;93(3):519-21.
118. Centers of Disease Control and Prevention (CDC). Achievements in public health. Reduction in perinatal transmission of HIV infection-United States, 1985-2005. MMWR Morb Mortal Wkly Rep. 2006;55(21):592-7.
119. Neri D, Somarriba GA, Schaefer NN, Chaparro AI, Scott GB, Lopez-Mitnik G, Ludwig DA, Miller TL. Growth and body composition of uninfected children exposed to human immunodeficiency virus: comparison with a contemporary cohort and United States national standards. J Pediatr. 2013; Jan 26 [Epub ahead of print].
120. Mofenson LM, Brady MT, Danner SP, Domingquez KL, Hazara R, Handelsman E, et al. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep. 2009;58(RR-11):1-166.
121. 2 HIV multicenter study. Am Heart J. 2000;140(4):575-84.
122. Lipshultz SE, Fisher SD, Lai WW, Miller TL. Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. AIDS. 2003;17(Suppl 1):S96-122.
123. Lipshultz SE, Fisher SD, Lai WW, Miller TL. Cardiovascular monitoring and therapy for HIV-infected patients. Ann N Y Acad Sci. 2001;946:236-73.
124. Saidi AS, Moodie DS, Garson A, Jr., Lipshultz SE, Kaplan S, Lai WW, et al. Electrocardiography and 24-hour electrocardiographic ambulatory recording (Holter monitor) studies in children infected with human immunodeficiency virus type 1. The pediatric pulmonary and cardiac complications of vertically transmitted HIV-1 infection study group. Pediatr Cardiol. 2000;21(3):189-96.
125. Ratnasamy C, Kinnamon DD, Lipshultz SE, Rusconi P. Associations between neurohormonal and inflammatory activation and heart failure in children. Am Heart J. 2008;155:527-33.
126. Rusconi PG, Ludwig DA, Ratnasamy C, Mas R, Harmon WG, Colan SD, et al. Serial measurements of serum NT-proBNP as markers of left ventricular systolic function and remodeling in children with heart failure. Am Heart J. 2010;160:776-83.